SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. Can J Urol 2005; 12 (Suppl. 1): 6670
  • 2
    Bukowski RM. Renal cell carcinoma: a new era? Clin Genitourin Cancer 2005; 4: 155
  • 3
    Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med 2005; 353: 247790
  • 4
    Mancuso A, Sternberg CN. What’s new in the treatment of metastatic kidney cancer? BJU Int 2005; 95: 117180
  • 5
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 101127
  • 6
    Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 69977000
  • 7
    Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 94954
  • 8
    Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT, Finkel T. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999; 255: 5458
  • 9
    Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62: 372935
  • 10
    Dasgupta P, Sun J, Wang S et al. Disruption of the Rb – Raf−1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004; 24: 952741
  • 11
    Lindsey H. Bevacizumab and erlotinib show promise for kidney cancer. Lancet Oncol 2006; 7: 15
  • 12
    Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005; 104: 232333
  • 13
    Fabian MA, Biggs WH 3rd, Treiber DK et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 32936
  • 14
    Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 9719
  • 15
    Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 2005; 96: 28690
  • 16
    Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1624
  • 17
    Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 251624
  • 18
    Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 11524
  • 19
    De Mulder PH, Roigas J, Gillessen S et al. A phase II study of sunitinib administered in a continous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl.): 18S
  • 20
    Rini BI. Sorafenib. Expert Opin Pharmacother 2006; 7: 45361
  • 21
    Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 250512
  • 22
    Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 12534
  • 23
    Eisen T, Bukowski RM, Staehler M et al.; TARGET Clinical Trial Group. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl): 18S
  • 24
    Lamuraglia M, Lassau N, Chami L et al. Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: a prospective study. Proc Annu Meet Am Soc Clin Oncol 2005; 23: 209s
  • 25
    Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2006; 28: 3163
  • 26
    Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 1227
  • 27
    Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17: 48794
  • 28
    Elit L. Drug evaluation: AP-23573 – an mTOR inhibitor for the treatment of cancer. IDrugs 2006; 9: 63644
  • 29
    Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 90918
  • 30
    Smith JW, Yo K-J, Dutcher J et al. Update of a phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 2004; 22 (Suppl): 384
  • 31
    Hudes G, Carducci M, Tomczak P et al. A phase III, randomized, 3-arm study of temsiorolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl): 18S
  • 32
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 253040
  • 33
    Tabernero J, Rojo F, Burris H et al. Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol 2005; 23 (Suppl.): 193s
  • 34
    Rivera VM, Kreisberg JI, Mita MM et al. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. Proc Annu Meet Am Soc Clin Oncol 2005; 23 (Suppl.): 200s
  • 35
    Zafar Y, Bendell J, Lager J et al. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl.): 145s
  • 36
    Sternberg CN. Pazopanib overview: an oral multi-target tyrosine kinase inhibitor. First International Kidney Cancer Symposium 289 April 2006, Madrid, Spain
  • 37
    Rini B, Rixe O, Bukowski R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer. Proc Annu Meet Am Soc Clin Oncol 2005; 23 (Suppl): 380s
  • 38
    George D, Michaelson D, Oh WK et al. Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 2003; 22
  • 39
    Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 250212
  • 40
    Ravaud A, Gardner J, Hwkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). Proc Annu Meet Am Soc Clin Oncol 2006; 24: 18s
  • 41
    Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 273343
  • 42
    Sosman JA, Flaherty K, Atkins MB et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). Proc Annu Meet Am Soc Clin Oncol 2006; 24: (Suppl): 18s
  • 43
    Azad NS, Posadas EM, Kwitkowski VE et al. C. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl.): 18S
  • 44
    Rini BI, George DJ, Michaelson MD et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proc Annu Meet Am Soc Clin Oncol 2006; 24 (Suppl.): 18s
  • 45
    Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004; 10: 6310S4S